Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer

Eli Lilly, Indianapolis, Indiana, United States
Journal of Clinical Oncology (Impact Factor: 18.43). 02/2009; 27(4):591-8. DOI: 10.1200/JCO.2008.17.1405
Source: PubMed


Gemcitabine plus carboplatin (GC) is active as front-line treatment for advanced non-small-cell lung cancer (NSCLC). For patients without progression, timing of second-line chemotherapy for optimum clinical benefit remains uncertain. This phase III, randomized trial assessed the efficacy and safety of docetaxel administered either immediately after GC or at disease progression.
The chemotherapy-naïve patients enrolled had either stage IIIB NSCLC with pleural effusion or stage IV NSCLC. Gemcitabine (1,000 mg/m(2)) was administered on days 1 and 8 followed by carboplatin (area under the curve = 5) on day 1. After four 21-day cycles, patients who did not have progression were randomly assigned either to an immediate docetaxel group (docetaxel 75 mg/m(2) on day 1 every 21 days, with maximum of six cycles) or to a delayed docetaxel group. The primary end point was overall survival (OS) measured from random assignment. Additional analyses included tumor response, toxicity, progression-free survival (PFS), and quality of life (QOL).
Enrollment totaled 566 patients; 398 patients completed GC; 309 patients were randomly assigned equally to the two docetaxel treatment groups. Toxicity profiles were generally comparable for the docetaxel groups. Median PFS for immediate docetaxel (5.7 months) was significantly greater (P = .0001) than for delayed docetaxel (2.7 months). Median OS for immediate docetaxel (12.3 months) was greater than for delayed docetaxel (9.7 months), but the difference was not statistically significant (P = .0853). QOL results were not statistically different (P = .76) between docetaxel groups.
We observed a statistically significant improvement in PFS and a nonstatistically significant increase in OS when docetaxel was administered immediately after front-line GC, without increasing toxicity or decreasing QOL.

Download full-text


Available from: Panos Fidias, Sep 25, 2014
  • Source
    • "The study showed a significant 3 months improvement in PFS and a non-statistically significant 2.5 months increase in OS in favor of the “immediate” docetaxel arm, with no increase in toxicity or decrease in QOL. Even though the patients in the delayed arm were carefully assessed and followed and that docetaxel was available to all of these patients, 37.2% of the patients in this arm did not receive docetaxel due to a rapid disease progression or a rapid PS decline (14). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of lung cancer had evolved during the last decade with the introduction of new chemotherapeutic regimens and targeted therapies. However, the maximum benefit reached after first-line therapy is limited by the cumulative toxicity of platinum drugs and the subsequent deterioration in performance status in a high percentage of patients who end up receiving not more than one line of treatment. Maintenance therapy had been introduced and evaluated in many large randomized trials showing a delay in tumor progression and an improvement in overall survival. This effective strategy should be taken into account when discussing the initial treatment plan and tailored according to the preferences of both patients and physicians.
    Full-text · Article · Aug 2014 · Frontiers in Oncology
  • Source
    • "The rationale for this strategy is that continuous treatment could effectively delay disease progression and improve survival. Nowadays, various agents have been applied in maintenance regimens, such as bevacizumab,36,37 cetuximab,38,39 docetaxel,40 gemcitabine,41 and pemetrexed,42,43 for switching or continuous maintenance therapy. However, of interest, the most robust results were observed in clinical trials that evaluated EGFR TKIs (erlotinib or gefitinib) as switch maintenance agents (Table 3). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been demonstrated to improve responses and clinical outcomes significantly in patients with advanced non-small-cell lung cancer (NSCLC). In retrospective subgroup analyses of several studies, patients with Asian ethnicity (including Chinese) are a subpopulation who responds well to EGFR TKI therapy. Since EGFR-mutation status has emerged as an important predictor of a substantially increased benefit, the high mutation rate in the Asian (including Chinese) population could be the explanation for a superior benefit from EGFR TKI therapy. Erlotinib (Tarceva®), one of the EGFR TKIs, has been proved to be effective in second- and third-line therapy, and furthermore in first-line and maintenance settings. In this review, we summarize current data of clinical trials with erlotinib and discuss its role in the targeted treatment of NSCLC in Chinese patients.
    Full-text · Article · Feb 2014 · OncoTargets and Therapy
  • Source
    • "In contrast, the SATURN trial found that erlotinib as a switch maintenance agent only yielded an OS benefit for patients with SD after induction (HR = 0.72 SD versus HR = 0.90 for patients with a tumor response),10 an outcome reflected in the maintenance indication for which erlotinib is approved for treatment in Europe. In a separate study by Fidias et al.,20 docetaxel was found to be effective as a switch maintenance agent only for the cohort of patients with a tumor response after induction (HR = 0.61 versus 1.02 for patients with SD).4 Results from the study by Pérol et al.11 led to the suggestion that induction response may affect survival results when using continuation maintenance. The post hoc analyses reported herein sought to further explore the initial PARAMOUNT finding. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance significantly reduced the risk of disease progression (hazard ratio = 0.62) and death (hazard ratio = 0.78) versus placebo in patients with advanced nonsquamous non-small-cell lung cancer. To further understand the survival data, descriptive subgroup analyses were undertaken. Nine hundred thirty-nine patients received induction therapy (four 21-day cycles pemetrexed 500 mg/m and cisplatin 75 mg/m), after which 539 nonprogressing patients with an Eastern Cooperative Oncology Group performance status (PS) of 0/1 were randomized (2:1) to maintenance pemetrexed (500 mg/m) cycles or placebo until disease progression. Baseline characteristics of patients surviving for longer periods were comparable to patients surviving shorter periods, suggesting overall survival (OS) benefit for all subgroups of patients on maintenance therapy. An examination of type and severity of induction adverse events also found no association with survival duration. Response to induction (tumor response versus stable disease) was not determinate of pemetrexed maintenance OS outcome as assessed by waterfall plot and scattergrams and by the distribution of patients among various OS intervals. The length of the interval before beginning maintenance therapy (<7 days versus ≥7/≤30 days) also did not impact the survival results. PS, a known prognostic factor, was the only baseline characteristic associated with improved OS; however, both PS 0 and PS 1 patients exhibited a survival benefit from pemetrexed maintenance. In PARAMOUNT, the OS benefit was seen across all subgroups. Other than PS, no baseline or clinical parameter clearly identified a subgroup more likely to benefit. Maintenance treatment decisions should be made on an individual basis.
    Full-text · Article · Feb 2014 · Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
Show more